drugset / Trial / NCT04654676
DPP4 Inhibitor on Glycemic Variability
NaSingle-groupOpen-labelTreatment
Summary
The investigators conducted a prospective study in patients with T2DM on twice daily MHI with or without metformin therapy. Blinded continuous glucose monitoring was performed at baseline and following 6 weeks of Vildagliptin therapy.
Timeline
- Start
- 2018-09-15
- Primary completion
- 2019-08-31
- Completion
- 2019-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vildagliptin | Other / unclassified | 50 mg | — |